Baseline characteristics and patient disposition
| Ozurdex+laser N=40 | Laser N=40 | |
|---|---|---|
| Number of patients (eyes), n | 40 | 40 |
| Sex, n (%) | ||
| Males | 34 (85.0) | 32 (80.0) |
| Females | 6 (15.0) | 8 (20.0) |
| Age (years), mean (SD) | 65.6 (10.6) | 61.1 (12.8) |
| Ethnicity, n (%) | ||
| Asian or Asian British | 14 (35.0) | 14 (35.0) |
| Black or Black British | 7 (17.5) | 7 (17.5) |
| White or White British | 16 (40.0) | 16 (40.0) |
| Other | 3 (7.5) | 3 (7.5) |
| Diabetes, n (%) | ||
| Type 1 | 2 (5.0) | 4 (10.0) |
| Type 2 | 38 (95.0) | 36 (90.0) |
| Duration of DM (years), median (IQR) | 15 (11, 20) | 15 (9, 22.5) |
| HbA1c (%), mean (SD) | 7.9 (1.2) | 8.0 (1.4) |
| Systolic BP (mm Hg), mean (SD) | 130.7 (16.6) | 130.8 (16.0) |
| Diastolic BP (mm Hg), mean (SD) | 72.0 (9.4) | 76.1 (9.2) |
| ETDRS BCVA, mean (SD) | 66.1 (7.3) | 66.6 (7.7) |
| Visual acuity group, n (%) | ||
| 54–66 letters | 22 (55.0) | 21 (52.5) |
| 67–78 letters | 18 (45.0) | 19 (47.5)* |
| Duration of CSMO (months), median (IQR) | 25.5 (7.5, 40.5) | 41 (23.5, 83.5) |
| Number of prior MLTs, median (IQR) | 2 (1, 3) | 3 (2, 4) |
| Prior anti-VEGF therapy | 2 | 2 |
| Prior steroid therapy | None | 1 |
| CST (μm), median (IQR) | 459 (373, 533) | 452 (407.5, 559) |
| Lens status, n (%) | ||
| Pseudophakic | 13 (32.5) | 13 (32.5) |
| Phakic | 27 (67.5) | 27 (67.5) |
| Previous treatment for glaucoma, n (%) | 1 (2.5) | 1 (2.5) |
All percentages are out of N.
*One participant with 81 ETDRS letters was randomised in error.
BCA, best corrected visual acuity; BP, blood pressure; CST, central subfield thickness; DM, diabetes mellitus; CSMO, clinically significant macular oedema; MLT, macular laser therapy; n, number of participants/eyes; N, total number of participants/eyes; VEGF, vascular endothelial growth factor.